GB491

· Genor Biopharma Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for GB491, covering 2023-05-09 to 2024-10-10. Get the full timeline:

Most recent: Clinical Trial Update: GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer [Phase 3]